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Abstract
The human lens contains three kynurenine UV filters, 3-hydroxykynurenine O-β-Dglucoside (3OHKynG), kynurenine (Kyn) and 3-hydroxykynurenine (3OHKyn), and it
absorbs UV light in the 300-400 nm region due to their presence. UV filters may also
prevent UV-induced photodamage to the retina and lens. After middle age, the UV
filters, 3OHKynG and Kyn become bound progressively to proteins in the centre of our
lenses. This feature is, in part, responsible for normal age-dependant human lens
colouration.
To provide proof that 3OHKyn is bound to normal human lenses, model studies were
undertaken. Cysteine (Cys), histidine (His) and lysine (Lys) residues in lens proteins
had been previously shown to bind to UV filters in vivo, therefore adducts of these
amino acids and 3OHKyn were synthesised and characterised by mass spectrometry,
fluorescence, UV-visible and NMR spectroscopy in Chapter 2. The stability properties
of each of the 3OHKyn amino acid adducts were also determined, with incubations
performed at pH 4.0 and pH 7.2. 3OHKyn-t-Boc-His was identified as the most stable
of the three adducts. 3OHKyn-t-Boc-Lys and 3OHKyn-Cys both decomposed at pH 7.2
forming numerous oxidation products. The stability of each adduct to acid hydrolysis
was also examined.
In Chapter 3, calf lens protein was incubated with 3OHKyn, and acid hydrolysis showed
that Cys was the primary site of modification when the incubation was undertaken at pH
7.2. However, when the incubation was undertaken at a higher pH (for example, pH
9.5), 3OHKyn readily modified Cys, His and Lys residues. Previously acid hydrolysis
of human lens protein had identified Kyn attachment to the proteins. However, acid
hydrolysis was not an appropriate method for detecting 3OHKyn attached to human lens
proteins because 3OHKynG is also bound to human lens proteins. Therefore, a new
assay was developed, and it was found that 3OHKyn does indeed bind to human lens
proteins in an age-dependant manner. The assay also provides data for 3OHKynG and
Kyn attachment to human lens proteins.
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In Chapter 3, α-crystallin was also incubated with 3OHKyn under low oxygen tension,
and the findings from this study showed that 3OHKyn modified the Cys residue in αAcrystallin. In addition, oxidation of methionine and tryptophan was observed. Agerelated nuclear cataract is associated with colouration, insolubilisation and extensive
oxidation of Cys and methionine residues. It appears that 3OHKyn in the lens may
promote the oxidation and modifications of proteins, and may contribute to oxidative
stress in the human lens.
In Chapter 4, the aim was to examine if 3OHKyn could act as a crosslinker of cataract
lens proteins. 3OHKyn is known to readily oxidise and yield highly reactive species. It
was therefore proposed that 3OHKyn bound to lens proteins could promote
crosslinking, insolubilisation and colouration of lens proteins following formation of
oxidised species. 3OHKyn amino acid adducts were incubated with excess amino acids,
and the resulting products examined. These compounds may be analogous to those that
would form in a cataract lens. In addition, 3OHKyn-modified protein was incubated and
the products were examined by SDS-PAGE, fluorescence spectroscopy and mass
spectrometry. Results showed that 3OHKyn, under the conditions used, does not
crosslink lens protein. Proof of the hypothesis that 3OHKyn crosslinks proteins in the
lens requires the isolation of characteristic chemical markers from cataract lens proteins
that contain the modified 3OHKyn molecules.
In Chapter 5, the aim was to isolate novel compounds from the hydrolysates of human
cataract lens proteins and to determine their chemical properties.
Overall this thesis provides evidence that 3OHKyn plays a role in the post-translational
modification of normal human lens proteins, and it also provides preliminary data on the
role of 3OHKyn in human cataract.
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